Diabetic Foot Ulcers – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Diabetic Foot Ulcers – Drugs In Development, 2023’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
- The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adepthera LLCAegleStem Therapeutics
Alan Laboratories Inc
Anterogen Co Ltd
Aposcience AG
APstem Therapeutics Inc
AptaBio Therapeutics Inc
Asia Stem Cell Regenerative Pharmaceutical Co Ltd
Beijing Huafeng Biotechnology Co Ltd
Bio-Bank Corp
Biofilm Pharma
BioTissue Inc
Blue Blood Biotech Corp
Canton Biotechnologies Inc
Cell2Cure Aps
Cellics Therapeutics Inc
Celloryx AG
Cellresearch Corp Pte Ltd
Ceria Therapeutics Inc
Chiesi Farmaceutici SpA
Chrysalis BioTherapeutics Inc
CK Regeon Inc
CSA Biotechnologies LLC
Cynata Therapeutics Ltd
Cytora Ltd
Destiny Pharma Plc
Elphis Cell Therapeutics Co Ltd
Energenesis Biomedical Co Ltd
Health & Biotech Co Ltd
Hoth Therapeutics Inc
Ilya Pharma AB
Lakewood-Amedex Inc
Madam Therapeutics BV
Mallinckrodt Plc
MangoGen Pharma Inc
MediWound Ltd
Mend Therapeutics
MimeTech Srl
Mirae Cell Bio Co Ltd
NovaLead Pharma Pvt Ltd
NOxy Health Products LLC
OliX Pharmaceuticals Inc
Omnio AB
Perpetuum BV
PHAXIAM Therapeutics SA
Promore Pharma AB
Qilu Pharmaceutical Co Ltd
Recce Pharmaceuticals Ltd
RegenETP Inc
RegenInnopharm Inc
Remedor Biomed Ltd
RHEACELL GmbH & Co KG
SaNOtize Research and Development Corp
Scarless Laboratories Inc
Selsym Biotech Inc
SERDA Therapeutics BV
Serodus ASA
Stempeutics Research Pvt Ltd
TechnoPhage SA
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Topadur Pharma AG
Transwell Biotech Co Ltd
Unicyte AG
University of Arizona
Vasomune Therapeutics Inc
Venturis Therapeutics Inc
Zhittya Genesis Medicine Inc
ZZ Biotech LLC